2. Signaling Pathways
  3. Vitamin D Related/Nuclear Receptor
  4. VD/VDR
  5. VD/VDR Agonist

VD/VDR Agonist

VD/VDR Agonists (14):

Cat. No. Product Name Effect Purity
  • HY-10002
    Calcitriol
    		Agonist 99.94%
    Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.
  • HY-50919
    Paricalcitol
    		Agonist 99.96%
    Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
  • HY-32341
    Seocalcitol
    		Agonist 99.51%
    Seocalcitol is a vitamin D analog, binds vitamin D receptor protein from human osteosarcoma MG-63 cells with Kd of 0.27 nM.
  • HY-12398
    TEI-9647
    		Agonist 99.88%
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease.
  • HY-32344
    Inecalcitol
    		Agonist
    Inecalcitol (TX 522), a unique vitamin D3 analog, is an orally active vitamin D receptor (VDR) agonist with a Kd of 0.53 nM. Inecalcitol can induce cell apoptosis and has potent anticancer activities. Inecalcitol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-32345
    Elocalcitol
    		Agonist 99.2%
    Elocalcitol (BXL-628) is a selective, orally active vitamin D receptor (VDR) agonist. Elocalcitol shows anti-inflammatory activity. Elocalcitol inhibits growth of prostate cancer cells.
  • HY-77278
    25-Hydroxytachysterol3
    		Agonist 98.89%
    25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1.
  • HY-131961
    Triciferol
    		Agonist 98.61%
    Triciferol functions as a multiple ligand with combined VDR agonist and HDAC antagonist activities. Triciferol binds directly to the VDR (IC50=87 nM), and functions as an agonist with 1,25D-like potency on several 1,25D target genes. Triciferol induces marked tubulin hyperacetylation, and augments histone acetylation. Antiproliferative and cytotoxic activities.
  • HY-114310
    VDR agonist 1
    		Agonist
    VDR agonist 1 (compound 28) is a nonsteroidal Vitamin D receptor (VDR) agonist, with an IC50 of 690 nM in MCF-7 cells. VDR agonist 1 arrests the cell cycle through the up-regulation of p21 and p27, promotes apoptosis by increasing the expression of BAX and decrease the expression of Bcl-2.
  • HY-50919R
    Paricalcitol (Standard)
    		Agonist
    Paricalcitol (Standard) is the analytical standard of Paricalcitol. This product is intended for research and analytical applications. Paricalcitol, a vitamin D analogue, is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.
  • HY-149899
    VDR agonist 2
    		Agonist
    VDR agonist 2 (compound 16i) is a VDR (vitamin D receptor) agonist that can effectively inhibit TGF-β1-induced activation of hepatic stellate cells (HSC). VDR agonist 2 has significant anti-hepatic fibrosis effects both in vitro and in vivo.
  • HY-14863
    Lunacalcipol
    		Agonist
    Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT).
  • HY-161778
    ZG-126
    		Agonist
    ZG-126 is an agonist for vitamin D receptor (VDR) and an inhibitor for histone deacetylase (HDAC) (IC50=0.63-67.6 μM). ZG-126 exhibits cytotoxicity in cancer cells MDA-MB-231 and 4T1. ZG-126 exhibits antitumor and anti-metastatic efficacy against melanoma and triple-negative breast cancer (TNBC) in mouse models. ZG-126 also exhibits anti-inflammatory activity, through the reduction of macrophage infiltration and immunosuppressive M2-polarization.
  • HY-10002R
    Calcitriol (Standard)
    		Agonist
    Calcitriol (Standard) is the analytical standard of Calcitriol. This product is intended for research and analytical applications. Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.